Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$3.38M-$3.38MN/M vs Q3 2023 EPS Diluted-$1.03-$1.03N/M vs Q3 2023 Operating Income-$3,424,853N/M Operating Cash Flowderived-$3,602,608N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Oct 30, 2024 · 30 d after period end